5 Stocks Pushing The Health Care Sector Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 35 points (0.3%) at 14,006 as of Tuesday, Feb. 12, 2013, 12:05 PM ET. The NYSE advances/declines ratio sits at 1,786 issues advancing vs. 1,060 declining with 154 unchanged.

The Health Care sector currently sits up 0.2% versus the S&P 500, which is up 0.1%.

TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today:

5. Alexion Pharmaceuticals ( ALXN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Alexion Pharmaceuticals is down $1.10 (-1.2%) to $91.20 on average volume Thus far, 910,435 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $91.09-$92.43 after having opened the day at $92.34 as compared to the previous trading day's close of $92.30.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologic therapeutic products in the United States, Europe, Latin America, Japan, and the Asia Pacific. Alexion Pharmaceuticals has a market cap of $18.2 billion and is part of the drugs industry. The company has a P/E ratio of 82.9, above the S&P 500 P/E ratio of 17.7. Shares are down 0.1% year to date as of the close of trading on Monday. Currently there are 15 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Alexion Pharmaceuticals Ratings Report now.

It's Official: Action Alerts PLUS beats the S&P 500 with Dividends Reinvested! Cramer and Link were up 16.72% in 2012. Were you? See what they are trading for 14-days FREE

If you liked this article you might like

Alexion Could Target Sage, Ra Pharma: Analyst

Dow, S&P 500 and Nasdaq at New Records as Promise of Tax Reform Boosts Banks

Stocks Back at Highs as Apple Gains on iPhone 8, iPhone X Release

Tech in Wait-and-See Mode Ahead of Apple Event, Financials Rise on Tax Talk

Stocks Come Off Highs as Apple Wait Counters Boost From Tax Reform Talk